Koninklijke Philips N.V. (RYLPF)
| Previous close | 20.51 |
| Open | 20.51 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 20.51 - 20.51 |
| 52-week range | 17.78 - 24.18 |
| Volume | |
| Avg. volume | 5,175 |
| Market cap | 18.595B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 12 May 2022 |
| 1y target est | N/A |
- Zacks
Philips (PHG) Agrees to a Consent Decree With DOJ and FDA
Philips (PHG) announces a consent decree with the U.S. government and FDA over Respironics' business recalls.
- Reuters
US federal court orders Philips to restrict production of sleep apnea devices
(Reuters) -A U.S. federal court issued a decree to restrict the production and sale of Philips' new sleep apnea machines at several facilities in the country, the Food and Drug Administration said on Tuesday. The U.S. District Court for the Western District of Pennsylvania has entered into what is known as a consent decree against the company's subsidiary Philips Respironics to curb the sale and production until certain requirements are met. In January, the Dutch health technology company had said that it will not sell new devices to treat sleep apnea in the United States in the coming years as it works to comply with a settlement with the FDA.
- Reuters
UPDATE 3-US federal court orders Philips to restrict production of sleep apnea devices
A U.S. federal court issued a decree to restrict the production and sale of Philips' new sleep apnea machines at several facilities in the country, the Food and Drug Administration said on Tuesday. The U.S. District Court for the Western District of Pennsylvania has entered into what is known as a consent decree against the company's subsidiary Philips Respironics to curb the sale and production until certain requirements are met. In January, the Dutch health technology company had said that it will not sell new devices to treat sleep apnea in the United States in the coming years as it works to comply with a settlement with the FDA.
